



University of Groningen

Corrigendum to 'A report on the status of vaccination in Europe' [Vaccine 36 (2018) 4979-4992]

Sheikh, Shazia; Biundo, Eliana; Courcier, Soizic; Damm, Oliver; Launay, Odile; Maes, Edith; Marcos, Camelia; Matthews, Sam; Meijer, Catherina; Poscia, Andrea

Published in:
Vaccine

DOI:
[10.1016/j.vaccine.2019.01.038](https://doi.org/10.1016/j.vaccine.2019.01.038)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2019

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Sheikh, S., Biundo, E., Courcier, S., Damm, O., Launay, O., Maes, E., ... Begg, N. (2019). Corrigendum to 'A report on the status of vaccination in Europe' [Vaccine 36 (2018) 4979-4992]. *Vaccine*, 37(10), 1374-1376. <https://doi.org/10.1016/j.vaccine.2019.01.038>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.


Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.



Contents lists available at ScienceDirect

Vaccine

journal homepage: www.elsevier.com/locate/vaccine



Corrigendum

Corrigendum to ‘A report on the status of vaccination in Europe’ [Vaccine 36 (2018) 4979–4992]



Shazia Sheikh ^{a,*}, Eliana Biundo ^b, Soizic Courcier ^a, Oliver Damm ^c, Odile Launay ^d, Edith Maes ^b, Camelia Marcos ^a, Sam Matthews ^e, Catherina Meijer ^b, Andrea Poscia ^f, Maarten Postma ^{g,h,i}, Omer Saka ^b, Thomas Szucs ^j, Norman Begg ^a

^a GSK, Avenue Fleming 20, 1300 Wavre, Belgium

^b Deloitte Belgium, Luchthaven Nationaal 1 J, 1930 Zaventem, Belgium

^c Department of Health Economics and Health Care Management, School of Public Health, Bielefeld University, Universitätsstraße 25, 33615 Bielefeld, Germany

^d Université Paris Descartes, Sorbonne Paris Cité, Inserm CIC 1417, Assistance Publique Hôpitaux de Paris (APHP), CIC Cochin-Pasteur, rue du Faubourg St Jacques 27, 75679 Paris cedex 14, France

^e GSK, Great West Road 980, Brentford TW8 9GS, UK

^f Institute of Public Health, Università Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168 Rome, Italy

^g Unit of Pharmacotherapy, -Epidemiology & -Economics, University of Groningen, Groningen Research Institute of Pharmacy, Antonius Deusinglaan 1, 9713 AV Groningen, the Netherlands

^h Department of Health Sciences, University of Groningen, University Medical Center Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, the Netherlands

ⁱ Department of Economics, Econometrics & Finance, University of Groningen, Faculty of Economics & Business, Groningen, the Netherlands

^j European Center of Pharmaceutical Medicine, University of Basel, Klingelbergstrasse 61, 4056 Basel, Switzerland

The authors regret to inform about errors in Figs. 2 and 3 in the column for Bulgaria. The correct figures should be:

DOI of original article: <https://doi.org/10.1016/j.vaccine.2018.06.044>

* Corresponding author.

E-mail address: shazia.x.sheikh@gsk.com (S. Sheikh).

<https://doi.org/10.1016/j.vaccine.2019.01.038>

0264-410X/© 2019 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.

This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

UMV[28]	AT	BE	BG	HR	FI	FR	DE	GR	IT	NL	PL	RO	SP	SE	CH	UK
BCG	✗	✗	✓	✓	✗	✗	✗	✗	✗	✗	✓	✓	✗	✗	✗	✗
Hepatitis B	✓	✓	✓	✓	✗	✓	✓	✓	✓	✓	✓	✓	✓	✗	✓	✓
Polio	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Diphtheria	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Tetanus	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Pertussis	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Hib	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Pneumococcal	✓	✓	✓	✗	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Rotavirus	✓	✓	✓	✗	✓	✗	✓	✓	✓	✗	✓	✗	✗	✗	✗	✓
Measles	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Mumps	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Rubella	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Hepatitis A	✗	✗	✗	✗	✗	✗	✗	✓	✗	✗	✓	✗	✗	✗	✗	✗
Varicella	✓	✗	✗	✗	✓	✗	✓	✓	✓	✗	✗	✗	✓	✗	✓	✗
HPV	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✗	✓	✓	✓	✓
MenC	✓	✓	✗	✗	✗	✓	✓	✓	✓	✓	✓	✗	✓	✗	✓	✓
MenACWY	✓	✗	✗	✗	✗	✗	✗	✓	✓	✗	✓	✗	✗	✗	✗	✓
MenB	✓	✗	✗	✗	✗	✗	✗	✗	✓	✗	✓	✗	✗	✗	✗§	✓
Influenza	✓	✗	✗	✗	✓	✓	✗	✗	✗	✗	✓	✗	✗	✗	✗	✓
Legend	✓ Recommended for UMV								✗ Not recommended for UMV							
	Funded/reimbursed				Out-of-pocket (OOP)				Co-payment							
Abbreviations	AT: Austria, BE: Belgium, BG: Bulgaria, HR: Croatia, FI: Finland, FR: France, DE: Germany, GR: Greece, IT: Italy, NL: Netherlands, PL: Poland, RO: Romania; SP: Spain, SE: Sweden, CH: Switzerland§ (not licensed), UK: United Kingdom; BCG: Bacillus Calmette–Guérin; Hib: Haemophilus influenzae B; HPV: human papillomavirus; Men: meningitis; UMV: universal mass vaccination.															

Fig. 2. Recommended childhood and adolescent UMV vaccines by country and funding level (2017).

	AT	BE	BG	HR	FI	FR	DE	GR	IT	NL	PL	RO	SP	SE	CH	UK
UMV for Pregnant Women[28]																
Diphtheria	✗	✓	✗	✗	✗	✗	✗	✓	✓	✗	✓	✓	✓	✗	✓	✓
Tetanus	✗	✓	✗	✗	✗	✗	✗	✓	✓	✗	✓	✓	✓	✗	✓	✓
Pertussis	✓	✓	✗	✗	✗	✗	✗	✓	✓	✓	✓	✓	✓	✗	✓	✓
Influenza	✓	✓	✗	✓	✓	✓	✓	✓	✓	✗	✓	✓	✓	✓	✓	✓
UMV for Adults[28]																
Diphtheria	✓	✓	✓	✗	✓	✓	✓	✓	✓	✗	✓	✗	✓	✓	✓	✗
Tetanus	✓	✓	✓	✗	✓	✓	✓	✓	✓	✗	✓	✗	✓	✓	✓	✗
Pertussis	✓	✓	✗	✗	✓	✓	✓	✓	✓	✗	✓	✗	✓	✓	✓	✗
Hepatitis B	✗	✗	✗	✗	✗	✗	✗	✗	✗	✗	✓	✗	✗	✗	✗	✗
UMV for Older adults (≥60 or 65 years of age)[28]																
Zoster	✓	✗	✗	✗	✗	✓	✗	✓	✓	✗	✗	✗	✗	✗	✗	✓
Pneumococcal	✓	✓	✓	✗	✓	✗	✓	✓	✓	✗	✓	✗	✗	✗	✗	✓
Diphtheria	✓	✓	✓	✗	✓	✓	✓	✓	✓	✗	✓	✗	✓	✓	✓	✗
Tetanus	✓	✓	✓	✓	✓	✓	✓	✓	✓	✗	✓	✗	✓	✓	✓	✗
Pertussis	✓	✓	✗	✓	✓	✗	✓	✓	✓	✗	✓	✗	✗	✓	✓	✗
Influenza	✓	✓	✗	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Legend	✓ Recommended for UMV ✗ Not recommended for UMV															
	Funded/reimbursed					Out-of-pocket (OOP)					Co-payment					
Abbreviations	AT: Austria, BE: Belgium, BG: Bulgaria, HR: Croatia, FI: Finland, FR: France, DE: Germany, GR: Greece, IT: Italy, NL: Netherlands, PL: Poland, RO: Romania, SP: Spain, SE: Sweden, CH: Switzerland, UK: United Kingdom; UMV: universal mass vaccination.															

Fig. 3. Recommended vaccines by country and funding level for pregnant women, adults and older adults (2017).

The authors would like to apologise for any inconvenience caused.